{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:18:04Z","timestamp":1790543884154,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>To systematically evaluate the efficacy of teriparatide and bisphosphonates in preventing fractures in postmenopausal women with osteoporosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods:<\/jats:title>\n            <jats:p>We performed a systematic search of PubMed, Embase, and the Cochrane Library for randomized controlled trials (RCTs) that compared teriparatide and bisphosphonates for osteoporosis treatment. Searches were performed without language restrictions and included studies from beginning of time to March 2019. Two authors independently screened and extracted the selected article. The quality of the included studies was evaluated using the Cochrane system evaluation method. Data were extracted and analysed using RevMan 5.2 software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Nine RCTs were included for a total of 2990 postmenopausal women with osteoporosis. Of these, 1515 patients were treated with teriparatide and 1475 were treated with bisphosphonates. After pooling the data of 9 studies, there were significant differences between teriparatide and bisphosphonates [relative risk (RR): 0.61, 95% confidence interval (CI) (0.51, 0.74)] in the prevention of fractures according to different follow-up durations (<jats:italic toggle=\"yes\">P\u200a<\/jats:italic>&lt;\u200a.05), whatever alendronate [RR: 0.51, 95% CI (0.27, 0.95)] and other bisphosphonates [RR: 0.63, 95% CI (0.51, 0.77)]. In addition, we found significant differences between teriparatide and bisphosphonates in the prevention of vertebral fractures [RR: 0.47, 95% CI (0.35, 0.64)] and non-vertebral fractures [RR: 0.76, 95% CI (0.58,0.99)]. There were no significant differences in adverse effects between teriparatide and bisphosphonates [RR: 0.89, 95% CI (0.76, 1.03)].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Based on the results of our meta-analysis, teriparatide was better than bisphosphonates in preventing fractures in postmenopausal women with osteoporosis both in the short-term and long-term follow-up periods. Teriparatide was superior to bisphosphonates in preventing vertebral and non-vertebral fractures. These drugs did not differ in terms of their adverse effects. More high-quality studies are needed to compare other factors such as costs and adverse reactions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000024839","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T21:26:31Z","timestamp":1614374791000},"page":"e24839","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0690-0531","authenticated-orcid":false,"given":"YuLong","family":"Ouyang","sequence":"first","affiliation":[{"name":"Nanchang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShuiLin","family":"Chen","sequence":"additional","affiliation":[{"name":"The Fourth Affiliated Hospital of Nanchang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wan","sequence":"additional","affiliation":[{"name":"Nanchang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GuiHao","family":"Zheng","sequence":"additional","affiliation":[{"name":"Nanchang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1306-7592","authenticated-orcid":false,"given":"GuiCai","family":"Sun","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","article-title":"Osteoporosis","volume":"367","author":"Sambrook","year":"2006","journal-title":"Lancet"},{"key":"R2-20250504","first-page":"60","article-title":"Epidemiology of osteoporosis and osteoporotic fractures","volume":"61","author":"Kehler","year":"2014","journal-title":"Reumatizam"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.2147\/PPA.S118396","article-title":"Gender and age-related treatment compliance in patients with osteoporosis in Germany","volume":"10","author":"Hadji","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/CIA.S2134","article-title":"Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice","volume":"3","author":"Bock","year":"2008","journal-title":"Clin Interv Aging"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1249\/MSS.0b013e3181cbae22","article-title":"ASBMR's primer on the metabolic bone diseases and disorders of mineral metabolism, 7th edition","volume":"42","year":"2010","journal-title":"Medicine & Science in Sports & Exercise"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","article-title":"Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?","volume":"366","author":"Black","year":"2012","journal-title":"N Engl J Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1185\/030079904125004475","article-title":"Bone safety of long-term bisphosphonate treatment","volume":"20","author":"Rodan","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1358\/dot.2009.45.8.1410652","article-title":"Perspectives in the treatment and prevention of osteoporosis","volume":"45","author":"Gennari","year":"2009","journal-title":"Drugs Today"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: now and the future","volume":"377","author":"Rachner","year":"2011","journal-title":"Lancet"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1359\/jbmr.061011","article-title":"Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis","volume":"22","author":"Keaveny","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/jbmr.2804","article-title":"A longitudinal study of skeletal histomorphometry at 6 and 24 months across four bone envelopes in postmenopausal women with osteoporosis receiving teriparatide or zoledronic acid in the SHOTZ Trial","volume":"31","author":"Dempster","year":"2016","journal-title":"J Bone Miner Res"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2018.09.020","article-title":"Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis","volume":"120","author":"Diez-Perez","year":"2019","journal-title":"Bone"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijsu.2019.03.004","article-title":"Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: a meta-analysis","volume":"66","author":"Yuan","year":"2019","journal-title":"Int J Surg"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1742-1241.2008.01768.x","article-title":"Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial","volume":"62","author":"Anastasilakis","year":"2008","journal-title":"Int J Clin Pract"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"442","DOI":"10.12659\/MSM.881905","article-title":"Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life","volume":"17","author":"Panico","year":"2011","journal-title":"Med Sci Monit"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"e13341","DOI":"10.1097\/MD.0000000000013341","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis","volume":"97","author":"Deng","year":"2018","journal-title":"Medicine"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH (1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/gerona\/62.7.744","article-title":"Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures","volume":"62","author":"Ensrud","year":"2007","journal-title":"J Gerontol A Biol Sci Med Scie"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1185\/030079906X100276","article-title":"Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis","volume":"22","author":"Iwamoto","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"e6970","DOI":"10.1097\/MD.0000000000006970","article-title":"Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: a meta-analysis of randomized controlled trials","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine"},{"issue":"(2a)","key":"R31-20250504","doi-asserted-by":"crossref","first-page":"12S","DOI":"10.1016\/S0002-9343(97)90022-X","article-title":"The crippling consequences of fractures and their impact on quality of life","volume":"103","author":"Cooper","year":"1997","journal-title":"Am J Med"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","article-title":"Mortality after all major types of osteoporotic fracture in men and women: an observational study","volume":"353","author":"Center","year":"1999","journal-title":"Lancet"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"e26267","DOI":"10.1371\/journal.pone.0026267","article-title":"Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials","volume":"6","author":"Shen","year":"2011","journal-title":"PloS One"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4158\/EP161678.RA","article-title":"Clinical evaluation of cost efficacy of drugs for treatment of osteoporosis: a meta-analysis","volume":"23","author":"Albert","year":"2017","journal-title":"Endocrine Pract"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00198-009-0917-y","article-title":"Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status","volume":"20","author":"Langdahl","year":"2009","journal-title":"Osteoporos Int"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:16:59Z","timestamp":1746339419000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024839"}},"subtitle":["A protocol for systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024839","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]},"assertion":[{"value":"2020-01-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}